

and 2-ethylhexylacrylate-N-vinyl-2-pyrrolidone (TSR-sup.(R)-adhesive of the Sekisui Company).

4. (Currently Amended) A transdermal Transdermal system according to claim 1, ~~characterized by a content of comprising~~ 0.1 to 20% by weight, ~~preferably 1 to 15%~~ of (21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,20-d-ione in the matrix.
5. (Currently Amended) A transdermal Transdermal system according to claim 1, wherein the matrix comprises at least one crystallization inhibitor.
6. (Currently Amended) A transdermal Transdermal system according to claim 5, wherein the matrix comprises at least one N-vinyl lactam polymer. ~~such as N-vinyl-1-aza-cycloheptan-2-one homopolymer, N-vinyl piperidin-2-one homopolymer, polymers of vinylpyrrolidone such as polyvidone (Kollidon-sup.(R)) or co-polymers of vinylpyrrolidone with vinyl acetate (copovidones).~~
7. (Currently Amended) A transdermal Transdermal system according to claim 1, ~~characterized by further comprising an additional content of at least one of the following penetration enhancer intensifiers: Monovalent or multivalent alcohols such as ethanol, 1,2-propanediol or benzyl alcohol; saturated or unsaturated fatty alcohols with 8 to 18 carbon atoms, such as lauryl alcohol or cetyl alcohol; hydrocarbons such as mineral oil; saturated and unsaturated fatty acids with 8 to 18 carbon atoms such as stearic acid or oleic acid; fatty acid esters with up to 24 carbon atoms or dicarboxylic acid diesters with up to 24 carbon atoms, such as methyl ester, ethyl ester, isopropyl ester, butyl ester, sec-butyl ester, isobutyl ester, tert-butyl ester or monoglyceric acid ester of acetic acid, caproic acid, lauric acid, myristic acid, stearic acid and palmitic acid, phosphatide derivatives, such as lecithin, terpenes, urea and its derivatives or ethers, such as dimethyl isosorbide and diethylene glycol monoethyl ether.~~
8. (Currently Amended) A transdermal Transdermal system according to claim 7, ~~characterized by a content of at least one of the following wherein said penetration enhancer intensifier is~~ lauryl alcohol, 1,2-propanediol, ~~or methyl ester and especially the isopropyl ester~~

~~of myristic acid or oleic acid, diisopropyl adipate and diisopropyl sebacate, lauric acid and oleic acid, as well as mixtures thereof.~~

9. (Currently Amended) A transdermal ~~Transdermal~~ system according to claim 1, ~~characterized by further comprising~~ an additional content of at least one estrogen ~~such as estradiol, estriol, ethinylestradiol, derivatives thereof such as, for example, mono-esters and diesters such as estradiol 3,17-beta-dipropionate.~~

10. (Currently Amended) A transdermal ~~Transdermal~~ system according to claim 1, ~~characterized by further comprising~~ an additional content of at least one stabilizer.

Please add the following new claims:

11. (New) A transdermal system according to claim 1, comprising 1 to 15% of (21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,20-dione in the matrix.

12. (New) A transdermal system according to claim 6, wherein the matrix N-vinyl lactam polymer is a N-vinyl -1-aza-cycloheptan-2-one homopolymer, N-vinyl-piperidin-2-one homopolymer, a polymer of vinylpyrrolidone or a co-polymer of vinylpyrrolidone with vinyl acetate .

13. (New) A transdermal system according to claim 12, wherein the vinylpyrrolidone is polyvidone.

14. (New) A transdermal system according to claim 9, wherein said estrogen is estradiol, estriol, ethinylestradiol, or a derivative thereof.

15. (New) A transdermal system according to claim 9, wherein said estrogen is a mono-ester or a diester.

16. (New) A transdermal system according to claim 9, wherein said estrogen is

estradiol-3,17 betadipropionate.

17. (New) A transdermal system according to claim 7, wherein said penetration enhancer is a monovalent or multivalent alcohol; a saturated or unsaturated fatty alcohol with 8 to 18 carbon atoms; a hydrocarbon; a saturated or unsaturated fatty acid with 8 to 18 carbon atoms; a fatty acid ester with up to 24 carbon atoms or a dicarboxylic acid diester with up to 24 carbon atoms; a phosphatide derivative, a terpene, a urea or its derivative or ether; or diethylene glycol monoethyl ether.

18. (New) A transdermal system according to claim 7, wherein said penetration enhancer is an isopropyl ester of myristic acid, oleic acid, diisopropyl adipate, diisopropyl sebacate, lauric acid, oleic acid, as well as mixtures thereof.

19. (New) A transdermal system according to claim 7, wherein said monovalent or multivalent alcohol is ethanol, 1,2-propanediol or benzyl alcohol.

20. (New) A transdermal system according to claim 7, wherein said saturated or unsaturated fatty alcohol with 8 to 18 carbon atoms is lauryl alcohol or cetyl alcohol.

21. (New) A transdermal system according to claim 7, wherein said hydrocarbon is mineral oil.

22. (New) A transdermal system according to claim 7, wherein said saturated and unsaturated fatty acid with 8 to 18 carbon atoms is stearic acid or oleic acid.

23. (New) A transdermal system according to claim 7, wherein said fatty acid ester with up to 24 carbon atoms or said dicarboxylic acid diester with up to 24 carbon atoms is methyl ester, ethyl ester, isopropyl ester, butyl ester, sec-butyl ester, isobutyl ester, tert-butyl ester or monoglyceric acid ester of acetic acid, caproic acid, lauric acid, myristic acid, stearic acid, or palmitic acid.

24. (New) A transdermal system according to claim 7, wherein said a urea or its

derivative or ether is dimethyl isosorbide.

25. (New) A transdermal system according to claim 17, wherein said a phosphatide derivative is lecithin.

ai 26. (New) A transdermal system according to claim 1, wherein said stabilizer is beta-cyclodextrin.
